C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.040
+0.010 (0.33%)
At close: Mar 6, 2026, 4:00 PM EST
3.027
-0.013 (-0.44%)
After-hours: Mar 6, 2026, 7:14 PM EST
C4 Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 35.95 | 35.58 | 20.76 | 31.1 | 45.79 | Upgrade
|
| Revenue Growth (YoY) | 1.02% | 71.44% | -33.25% | -32.08% | 37.93% | Upgrade
|
| Cost of Revenue | 8.98 | 12.54 | 117.71 | 117.84 | 94.67 | Upgrade
|
| Gross Profit | 26.97 | 23.05 | -96.95 | -86.75 | -48.88 | Upgrade
|
| Selling, General & Admin | 36.2 | 42.12 | 42.08 | 42.79 | 33.25 | Upgrade
|
| Research & Development | 95.26 | 98.1 | - | - | - | Upgrade
|
| Operating Expenses | 131.46 | 140.22 | 42.08 | 42.79 | 33.25 | Upgrade
|
| Operating Income | -104.49 | -117.18 | -139.03 | -129.53 | -82.13 | Upgrade
|
| Interest Expense | - | - | -1.37 | -2.22 | -2.15 | Upgrade
|
| Interest & Investment Income | 7.61 | 9.03 | 6.03 | 4.29 | 2.27 | Upgrade
|
| EBT Excluding Unusual Items | -96.88 | -108.14 | -134.38 | -127.46 | -82.01 | Upgrade
|
| Merger & Restructuring Charges | - | -2.44 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 2.74 | 5.4 | 3.78 | -0.71 | -1.88 | Upgrade
|
| Asset Writedown | -10.73 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | -0.62 | - | - | Upgrade
|
| Pretax Income | -104.87 | -105.19 | -131.21 | -128.18 | -83.89 | Upgrade
|
| Income Tax Expense | 0.12 | 0.13 | 1.28 | - | - | Upgrade
|
| Net Income | -104.99 | -105.32 | -132.49 | -128.18 | -83.89 | Upgrade
|
| Net Income to Common | -104.99 | -105.32 | -132.49 | -128.18 | -83.89 | Upgrade
|
| Shares Outstanding (Basic) | 83 | 69 | 50 | 49 | 46 | Upgrade
|
| Shares Outstanding (Diluted) | 83 | 69 | 50 | 49 | 46 | Upgrade
|
| Shares Change (YoY) | 19.49% | 39.75% | 1.59% | 6.13% | 304.93% | Upgrade
|
| EPS (Basic) | -1.27 | -1.52 | -2.67 | -2.62 | -1.82 | Upgrade
|
| EPS (Diluted) | -1.27 | -1.52 | -2.67 | -2.62 | -1.82 | Upgrade
|
| Free Cash Flow | -99.3 | -65.34 | -108.55 | -111.44 | -88.24 | Upgrade
|
| Free Cash Flow Per Share | -1.20 | -0.94 | -2.19 | -2.28 | -1.92 | Upgrade
|
| Gross Margin | 75.03% | 64.76% | - | -278.96% | -106.76% | Upgrade
|
| Operating Margin | -290.68% | -329.30% | -669.83% | -416.56% | -179.39% | Upgrade
|
| Profit Margin | -292.08% | -295.96% | -638.34% | -412.19% | -183.23% | Upgrade
|
| Free Cash Flow Margin | -276.24% | -183.61% | -522.96% | -358.36% | -192.73% | Upgrade
|
| EBITDA | -102.53 | -115.36 | -137.15 | -127.86 | -80.64 | Upgrade
|
| EBITDA Margin | -285.23% | - | - | - | -176.13% | Upgrade
|
| D&A For EBITDA | 1.96 | 1.82 | 1.88 | 1.68 | 1.49 | Upgrade
|
| EBIT | -104.49 | -117.18 | -139.03 | -129.53 | -82.13 | Upgrade
|
| EBIT Margin | -290.68% | - | - | - | -179.39% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.